Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless).

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04006210
Recruitment Status : Not yet recruiting
First Posted : July 3, 2019
Last Update Posted : July 3, 2019
Sponsor:
Information provided by (Responsible Party):
NeuroDerm Ltd.

Brief Summary:

This is a multi-center, randomized, double blind, active controlled clinical Study. Following a screening period, eligible subjects will be enrolled to an open-label oral IR LD/CD adjustment period; then an open-label ND0612 conversion period; then after optimization periods subjects will be randomized to receive either ND0612 or its matching Placebo with IR LD/CD.

Subjects can continue to an optional open-label extension period for one year;


Condition or disease Intervention/treatment Phase
Parkinson's Disease Combination Product: ND0612 Solution for SC infusion Combination Product: Placebo for SC infusion Drug: Carbidopa and Levodopa 25mg/100mg Drug: Placebo for Carbidopa and Levodopa 25mg/100mg Phase 3

Detailed Description:

This is a phase III multi-center, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson's disease experiencing motor fluctuations.

This study is comprised of 6 periods:

  1. a Screening Period;
  2. an open-label oral IR-LD/CD Adjustment Period.
  3. an open-label ND0612 Conversion Period.
  4. a randomized, double-blind, double-dummy, active-controlled Maintenance Period.
  5. an optional open-label Treatment Extension; and
  6. a Safety Follow-up Period.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Blinded Site Rater, Blinded CRAs, active drugs and matching placebo are identical in their appearance.
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Estimated Study Start Date : August 28, 2019
Estimated Primary Completion Date : September 28, 2020
Estimated Study Completion Date : April 28, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Group A
ND0612 SC infusion + placebo IR-LD/CD + active IR-LD/CD (Carbidopa Levodopa USP tabs 25mg/100mg), for 24 hours.
Combination Product: ND0612 Solution for SC infusion
Levodopa Carbidopa solution administered SC via infusion pump

Drug: Carbidopa and Levodopa 25mg/100mg
Encapsulated Carbidopa and Levodopa USP 25mg/100mg

Drug: Placebo for Carbidopa and Levodopa 25mg/100mg
Encapsulated Placebo for Carbidopa and Levodopa USP 25mg/100mg

Active Comparator: Group B
Placebo for ND0612 SC infusion + placebo IR-LD/CD + active IR-LD/CD (Carbidopa Levodopa USP tabs 25mg/100mg), for 24 hours.
Combination Product: Placebo for SC infusion
Placebo solution administered SC via infusion pump

Drug: Carbidopa and Levodopa 25mg/100mg
Encapsulated Carbidopa and Levodopa USP 25mg/100mg

Drug: Placebo for Carbidopa and Levodopa 25mg/100mg
Encapsulated Placebo for Carbidopa and Levodopa USP 25mg/100mg




Primary Outcome Measures :
  1. The change from Baseline to the end of the double-blind assessment period in daily ON time without troublesome dyskinesia (sum of ON time without dyskinesia and ON time with non-troublesome dyskinesia) per patient diary. [ Time Frame: Baseline to DBDD Maintenance Period (12 weeks) ]

Secondary Outcome Measures :
  1. The change from Baseline to the end of the double-blind assessment period in OFF time per patient diary. [ Time Frame: Baseline to DBDD Maintenance Period (12 weeks) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female patients, aged ≥30 years.
  2. PD diagnosis consistent with the UK Brain Bank Criteria.
  3. Modified Hoehn & Yahr score ≤3 during ON.
  4. Average of ≥2.5 hours of OFF time (≥2 hours OFF every day) during waking hours as confirmed by patient diary over 3 days.
  5. Taking ≥4 levodopa doses/day (≥3 doses/day of Rytary) at a total daily dose of ≥400mg.

Exclusion Criteria:

  1. Atypical or secondary parkinsonism.
  2. Severe disabling dyskinesias.
  3. Previous neurosurgery for PD.
  4. Use of duodenal levodopa infusion (LCIG)* or apomorphine infusion.
  5. Use of the following medications: subcutaneous apomorphine injections, sublingual apomorphine, or inhaled levodopa within 4 weeks.
  6. Previous participation in ND0612 studies.
  7. History of significant skin conditions or disorders.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04006210


Contacts
Layout table for location contacts
Contact: Yael Ullmann, BPharm 972-547610102 Ullmann.y@neuroderm.com
Contact: Eti Lavi, MSc 972548886420 eti@neuroderm.com

Sponsors and Collaborators
NeuroDerm Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Alberto J Espay, MD, MSc University of Cincinnati OH, USA
Principal Investigator: Olivier Rascol, MD, PhD Toulouse University Hospital, France

Layout table for additonal information
Responsible Party: NeuroDerm Ltd.
ClinicalTrials.gov Identifier: NCT04006210     History of Changes
Other Study ID Numbers: ND0612-317
First Posted: July 3, 2019    Key Record Dates
Last Update Posted: July 3, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Levodopa
Carbidopa
Pharmaceutical Solutions
Antiparkinson Agents
Anti-Dyskinesia Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Aromatic Amino Acid Decarboxylase Inhibitors
Enzyme Inhibitors